ENGLEWOOD, Colo., Nov. 28, 2017 /PRNewswire/ — Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the launch of Natesto in the U.S. Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date. Additionally, in October, the number of physicians prescribing Natesto increased 16% from the previous month.
The Company reports the following prescription and prescriber growth for the one-month and three-month periods ending October 31, 2017:
Natesto total prescriptions for the month of October were 827, representing a 17% increase over September total prescriptions. New prescriptions for Natesto for the month of October increased to 495. The number of prescribers of Natesto for the month of October was 407, representing a 16% increase over September. New prescribers represented over 25% of total prescribers in October. Natesto total prescriptions were 2,263 for the three-month period ending October 2017, representing a 35% increase over the three-month period ending July 2017.
Josh Disbrow, Chief Executive Officer of Aytu BioScience commented, “Aytu is continuing to drive adoption of Natesto at an accelerated rate, and the Company is pleased with the ongoing positive reception by physicians and patients. The combination of a highly differentiated product profile and our sales force becoming increasingly proficient has resulted in all-time highs for Natesto in terms of both prescription levels and prescribers. We remain enthusiastic about the uptake of Natesto, particularly the large increase over these past three months, and we are on track to achieve cashflow breakeven in the quarters ahead based on our forecasted growth.”
The Company expects to continue to provide periodic updates on the ongoing launch of Natesto in the U.S.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”) and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis